Home › All Companies › CNSP › Annual Report

CNS Pharmaceuticals, Inc. (CNSP) — Annual Report

AI-Powered SEC Filing Analysis

← All CNSP filings
Latest Annual Report Filed: 2026-03-31

Key Insights

  • CNS Pharmaceuticals, Inc. (CNSP) has been actively raising capital through various equity offerings, including a January 2024 public offering and subsequent registered direct and private placement offerings, to fund its operations.
  • The company has entered into an at-the-market (ATM) sales agreement with AGP to provide additional financing flexibility, which has been utilized throughout 2024 and 2025.
  • The company has outstanding convertible notes and warrants that could result in additional dilution if exercised, which investors should monitor.
Sentiment: Neutral Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-31. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for CNS Pharmaceuticals, Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.